<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814201</url>
  </required_header>
  <id_info>
    <org_study_id>PI10-DR-DURU</org_study_id>
    <nct_id>NCT02814201</nct_id>
  </id_info>
  <brief_title>Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm</brief_title>
  <acronym>ERAMPPCI</acronym>
  <official_title>Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <brief_summary>
    <textblock>
      Action slowing has been demonstrated in many diseases. Parkinson's disease (PD) and&#xD;
      Huntington's disease (HD) are two neurodegenerative diseases affecting the basal ganglia,&#xD;
      particularly the medial globus pallidus, and the clinical expression of these two diseases is&#xD;
      characterized by a combination of motor and cognitive disorders, but with two opposing&#xD;
      patterns of dysfunction. Action slowing has been demonstrated in both of these diseases and&#xD;
      has been extensively studied in Parkinson's disease, suggesting a perceptive-cognitive&#xD;
      origin. Far fewer studies have been conducted in Huntington's disease. However, all of these&#xD;
      studies were performed with different methodologies in small cohorts and the value of the&#xD;
      proposed study is to use a validated and standardized computerized mental chronometry&#xD;
      paradigm, providing a better understanding of the mechanisms of action slowing in these two&#xD;
      diseases and to more clearly define a disease-specific profile.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SRT</measure>
    <time_frame>Day 0</time_frame>
    <description>simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase &quot;worst -off&quot; at the Parkinson's patient )</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">55</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson best-On</arm_group_label>
    <description>two hours after taking two tablets of 125 mg dispersible Modopar®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson worst-off</arm_group_label>
    <description>after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Huntington</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Data collected from the existing database</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SRT</intervention_name>
    <description>simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase &quot;worst -off&quot; at the Parkinson's patient )</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Huntington</arm_group_label>
    <arm_group_label>Parkinson best-On</arm_group_label>
    <arm_group_label>Parkinson worst-off</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Hoehn and Yahr stage 1 to 3 Parkinson's disease and patients with Shoulson&#xD;
        stage I and II Huntington's disease, in whom admission to the Neurology ward is scheduled&#xD;
        in the context of their follow-up, comprising a neuropsychological assessment (together&#xD;
        with an acute L-dopa administration test for Parkinsonian patients) will be included&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agreeing to participate in the study&#xD;
&#xD;
          -  French mother tongue&#xD;
&#xD;
          -  MMSE &gt; 20/30&#xD;
&#xD;
          -  Specific to the MP and MH:&#xD;
&#xD;
               -  Parkinson's disease:&#xD;
&#xD;
                    -  defined by the criteria of the UKPDSBB&#xD;
&#xD;
                    -  stage 1 , 2 or 3 Hoehn and Yahr (ON)&#xD;
&#xD;
                    -  age of onset of the disease known&#xD;
&#xD;
                    -  brain MRI performed during follow-up&#xD;
&#xD;
               -  Huntington disease :&#xD;
&#xD;
                    -  genetically defined (CAG &gt; 35)&#xD;
&#xD;
                    -  weaning neuroleptic ( Tercian® and Solian® : 2 days; Haldol® : 5 days ;&#xD;
                       Tiapridal® and Xenazine : 1 day ; Zyprexa® : 4 days)&#xD;
&#xD;
                    -  Early stage : Fahn and Shoulson I and II is a CFT score between 7 and 13&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Illiteracy, writing or reading difficulties&#xD;
&#xD;
          -  Visual perceptual auditory deficit or preventing reading, drawing, writing or&#xD;
             understanding instructions&#xD;
&#xD;
          -  Visual hallucinations&#xD;
&#xD;
          -  Significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic&#xD;
             heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic&#xD;
             alcoholism weaned or not)&#xD;
&#xD;
          -  Current or previous neurological diseases other than MH or MP: ischemic cerebral&#xD;
             vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes),&#xD;
             epilepsy requiring treatment.&#xD;
&#xD;
          -  Psychiatric disorders depression unless treated (stable treatment for 1 month)&#xD;
&#xD;
          -  Psychotropic treatment (except anxiolytic, antidepressant steady since 1 month)&#xD;
&#xD;
          -  Inability to achieve an autonomous operation without technical assistance over a&#xD;
             distance of 20 meters.&#xD;
&#xD;
          -  Inability to stand without technical assistance for 30 seconds.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre KRYSTKOWIAK, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Motor slowing</keyword>
  <keyword>Computerized mental chronometry paradigm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

